The recent cloning of the ligand of the c-Mpl hematopoietin receptor has indicated a major role for this cytokine in the development of megakaryocytes. In this study we have applied c-Mpl ligand (thrombopoietin [TPOI) in the setting of syngeneic transplantation in an attempt t o accelerate the reconstitution of platelets. Donor mice were treated with 20 kilounits (kU)/d TPO intraperitoneally (ip) for 5 days. This resulted in a 2.5-fold increment in platelet counts from 1,119 x 109/L t o 2,582 x 109/L (mean, n = 7). Total numbers of hematopoietic progenitor cells in bone marrow (BM) and spleen, as assessed in a colony-forming unit-granulocyte erythroid monocyte macrophage (CFU-GEMM) colony assay (55.3 v 38.6 x IO3 CFU/femur; 27.3 v 16.3 x IO3 CFU/spleen, mean, n = 7) as well as total numbers of burst-forming uniterythroid (BFU-E) (24.0 v 16.4 x 103/femur; 10.2 v 1.9 x IO3/ spleen, mean, n = 7). were significantly higher in TPOtreated donors than in saline-treated controls. Female Balb- T HAS BEEN hypothesized for many years that the production of platelets may be regulated by specific humeral factors.' Early experiments had shown that plasma or urine of thrombocytopenic animals contains an activity that promotes megakaryocytic colony formation and increases the size of marrow These activities were referred to as megakaryocyte colony-stimulating factor (Meg-CSF) or thrombopoietin (TPO). However, the low concentrations of these activities and the lack of suitable bioassays had hampered the identification of thrombopoietin for nearly 3 decades.
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The recent cloning and characterization of TPO has provided new insight in the regulation of megakaryocyte development and platelet production.""' The cloning of TPO was with equal cell numbers but given vehicle alone. In other experiments, IO5 BM cells were procured from TPO-treated donor mice and transplanted into lethally irradiated recipient mice. In comparison with animals transplanted with an equal number of BM cells derived from saline-treated controls, recipients of TPO-treated BM cells had significantly faster platelet recovery and higher platelet nadir counts (88 v30 x 109/L, mean, n = 20). Transplantation of TPO-treated BM cells also resulted in an accelerated recovery of erythrocytes and increased erythrocyte nadir counts (7.2 v 5.0 x lO"/L, mean, n = 20). At the day of platelet nadir (day 12 after transplantation) these animals had higher numbers of BFU-Es (770 v 422, mean, n = 5) in the marrow and also had higher reticulocyte counts (44O/,, v8O/,,, mean, n = 5) in the blood. Therefore, the accelerated recovery of erythrocytes may be a direct effect of TPO on erythropoiesis. Our results indicate that pretreatment of donor animals with TPO before marrow procurement may be an effective alternative method t o accelerate the reconstitution of platelets and erythrocytes after lethal irradiation and syngeneic stem cell transplantation. enabled by the recent discovery of the cellular proto-oncogene c-Mpl."-I3 This member of the hematopoietic receptor family exhibited significant homology to the erythropoietin (EPO) receptor and on the basis of several lines of evidence, was strongly suspected to play an important role in megakaryocytopoiesis. For example, c-Mpl mRNA was localized primarily to cells of the megakaryocytic lineage, including CD34-bearing cells, megakaryocytes, platelets and cell lines that displayed features of megakaryocytic differentiation.I4 In addition, antisense oligonucleotides against c-Mpl mRNA specifically suppressed the development of megakaryocytes in colony assays, but not of other lineages." Since then, several groups have cloned the ligand for c-Mpl and have provided evidence that this cytokine was indeed TPO. In semisolid cultures, recombinant murine TPO acts as a CSF and increases megakaryocyte progenitor cell numbers.'.'' It also induces differentiation of megakaryocytes.'.'" This effect was lineage specific; neither the numbers nor size of colony-forming units granulocyte-macrophage (Cm-GM) and burst-forming units-erythroid (BFU-E) colonies were altered. In vivo administration of TPO resulted in increased numbers of circulating platelets, with mice treated with recombinant murine (rmu) TPO for 5 days exhibiting a mean fourfold increase in platelet counts compared to controls treated with vehicle alone.'" The bone marrow (BM) and spleen of these animals showed increased numbers of large megakaryocytes, indicating that thrombocytosis was indeed caused by increased production of megakaryocytes. These results established that TPO is a major regulator of megakaryocyte development.
In the present study we have applied rmuTPO in a synge- For personal use only. on September 14, 2017. by guest www.bloodjournal.org From neic transplant model to study its possible thrombopoietic activities after myeloablative radiotherapy and transplantation. In particular, we have administered TPO to donor mice and have transplanted in vivo modified BM cells into lethally irradiated recipient animals to study hematopoietic reconstitution.
MATERIALS AND METHODS

Animals
Female Balb-C mice (age ranging from 8 to 12 weeks) were purchased from Broekman BV (Someren, The Netherlands). Mice were fed commercially available rodent chow and acidified water ad libitum. In transplant experiments, recipients were maintained in a pathogen-free environment and were fed water containing ciprofloxacin at a concentration of 1 mg/mL (Bayer Nederland BV, Mijdrecht, The Netherlands), polymyxine-B 70 pg/mL, and saccharose 2 g/lOO mL. In transplant experiments, recipient mice were placed in a polymethylmeta-acetate box and given total body irradiation (8.5 Gy, Philips SL 75-516 mV linear accelerator; Philips Medical Systems, Best, The Netherlands) divided in two parts in posterioranterior and anterior-posterior position, at a dose rate of 4 Gy/min.
Thromhopoietin
Murine recombinant thrombopoietin was provided as a serumfree medium containing 145 klJ/mL mouse TPO. Units of activity of TPO were defined in a BaF3hlPL-R cell proliferation assay, 50 U being the amount of TPO giving half-maximal proliferation. Mouse TPO samples were effective in colony-forming assays in a range of approximately 100 to 400 U/mL. In vivo activities were seen in the range of 20 to 40 kU/d in mice. The concentration of endotoxin was less than 0.05 U/mL as tested in the limulus amoebocyte lysate assay. For in vivo experiments, TPO was diluted to the desired concentration in endotoxin-free phosphate-buffered saline (PBS) and administered as intraperitoneal (ip) or subcutaneous (sc) injection.
Peripheral Blood (PB) Cell Counts
PB was obtained by tail hleeding or cardiac puncture. White blood cells (WBCs), red blood cells (RBCs), and platelets were counted on a Sysmex 800 counter (TOA Medical Electronics Co. Kobe, Japan). Manual neutrophil counts were performed after May-Griinwald Giemsa staining.
Preparation of Cell Suspensions
Blood-derived mononuclear cell (MC) suspensions were obtained by Ficoll separation (SD 1.077 g/cm', 4°C) as described previously." BM cells were procured by flushing the femur under sterile conditions with RPM1 1640 containing 500 pg/mL penicillin, 250 pg/mL streptomycin, and 2% fetal bovine serum (FBS) (GIBCO, Grand Island, NY). Single-cell suspensions of the spleen were prepared by mashing the organ and washing it once in RPM1 1640 with 2% FBS. In transplantation experiments, BM-derived MCs from TPO-treated donors or saline-treated controls were suspended in PBS.
Progenitor Cell Assays
CFU-GM were cultured as described previously.'x Briefly, BM cells were cultured in microtiter plates containing lo4 cells/well in semisolid medium in the presence of murine GM-CSF (1.25 ng/mL). PBMCs and spleen cells were cultured in 3.5-cm dishes containing 5 X 10' cells/mL and lo6 cells/mI,, respectively. Cells were cultured in a fully humidified atmosphere of 37°C containing 5% COz. After 6 days of culture the number of colonies (defined as aggregates of >20 cells) were scored using an inverted microscope. The CFUmix assay was performed in an identical fashion in 3.5-cm dishes in the presence of a combination of 1.25 ng/mL rmuGM-CSF, 2 U/ mL recombinant human (rhu) EPO, 25 ng/mL rmu interleukin-3 ( L 3) 5% transferrin, 5% devonized bovine serum albumin. 5% IO-' M'2 mercaptoethanol, and 7.56 Iscove's modified Dulbecco's medium (IMDM). After 6 to 7 days of culture (37"C, fully humidified atmosphere, 5% COz) the number of colony-forming cells was scored using an inverted microscope.
Experimental Protocol
Donor mice were treated with TPO (20 klJ/d) or saline administered as an ip or sc injection. After various time intervals animals were killed and blood, BM, and spleen were procured. Recipient animals were lethally irradiated (8.5 Gy) (day 0) and transplanted with BM cells within 4 hours after marrow procurement. From day 1 after transplantation, TPO (20 to 30 kU/d) or saline was administered as an ip or sc injection during a period of 5 to 14 days. Blood samples were taken after transplantation from individual recipients every 3 days by tail-vein bleeding.
Statistical Analysis
Differences were evaluated using the Student's t-tests. In the MANOVA analysis, groups were compared with respect to their course over time. The analysis was performed on the log values of the data. Values <.OS are considered statistically significant.
RESULTS
Effect cf Thromhopoietin on Hematopoietic Reconstitution After Lethal Irradiation and Transplantation
Recipient mice were lethally (8.5 Gy) irradiated and transplanted with 10' BM cells derived from steady-state donor mice. Groups of five mice were treated with TPO at a dose of 20 kU/d ip from days 1 through 5, days 3 through 7, or days 3 through 12 after transplantation. Control animals were transplanted with an equal amount of BM cells and administered saline at similar time intervals after transplantation. In comparison with saline-treated control recipients, TPO administration did not result in accelerated platelet reconstitution (Fig 1) . A dose of 30 kU/d sc administered from days 1 through 14 after transplantation was also ineffective in accelerating platelet recovery. Similarly, TPO treatment did not affect the reconstitution of WBCs or RBCs (data not shown).
Effect of Donor Treatment With TPO on Hematopoietic Reconstitution After Transplantation
Effect of TPO treatment on spleen and BM-derived hematopoietic cells. To assess the effect of transplantation of BM cells that were in vivo modified by TPO treatment, donor mice were treated with TPO for 5 consecutive days at a dose of 20 kU/d iplmouse. At day 5 , mice were killed and blood, BM, and spleen were procured. TPO treatment induced a 2.5-fold increase in the numbers of platelets, but had no effect on the number of WBCs and RBCs (Table 1) . TPO treatment resulted in increased numbers of CFU-GM and BFU-Es in the BM or spleen in comparison with salinetreated control mice (Table 2) . (Fig 2) . In addition, platelet nadir counts in recipients of in vivo TPO-modified BM cells were also higher than in recipients transplanted with an equal number of unmodified BM cells (88 v 30 X lo9 at day 12 after transplantation, mean of 20 mice , Fig 2) . Posttransplant treatment with TPO for 5 days (days 1 through 5, 20 kU/d ip) of recipients transplanted with TPO-modified BM cells did not result in a further acceleration of platelet reconstitution (Fig 2) . Reconstitution of neutrophils was similar for recipients of TPO-modified or unmodified BM cells (data not shown).
Effect of Transplanted Cell Dose on Hematopoietic Reconstitution
The possibility was considered that the lack of response to TPO administered after transplantation was related to the number of cells transplanted. In additional experiments, groups of 10 mice were transplanted with 3 X IO4 BM cells and treated with TPO (20 kU/d ip) or saline from days 3 through 12 after transplantation. The majority of these animals did not survive the lethal irradiation, indicating that the threshold cell dose for radioprotection in these animals was lo5 celldrecipient. Therefore, an effect of TPO on animals transplanted with lower cell numbers could not be evaluated appropriately. To further assess the effect of cell numbers on reconstitution of lethally irradiated recipient animals, recipients were transplanted with increasing numbers ( lo5, 3 X IO5, lo6 celldrecipient) of BM cells derived from TPOtreated donors or saline-treated controls. At all cell concentrations tested, platelet reconstitution was significantly enhanced in recipients of TPO-modified BM cells (Fig 3) . In both groups, treatment with TPO (20 kU/d ip, days 1 through 5 ) did not further accelerate platelet reconstitution (Fig 3) . In addition to an accelerated reconstitution of platelets, recipients of TPO-modified BM cells also exhibited accelerated reconstitution of erythrocytes (Fig 4) . The erythrocyte nadir counts were also significantly higher in these animals than in controls transplanted with an equal number of unmodified BM cells (7.2 v 5.0 X lO'?L, mean, n = 20). Experiments were performed to further substantiate that this effect was due to a direct activity of TPO on erythropoiesis and not related to differences in platelet counts and bleeding tendency. In this experiment recipient animals were not bled until day 12 after transplantation. At this time interval, the recipient mice were killed and the number of BM and blood-derived progenitor cells was assessed. Recipients of TPO-modified BM cells had a higher number of BFU-E colonies/femur (770 5 386 v 422 5 320, mean 5 SD, n = S) and higher reticulocytes 
DISCUSSION
In this study we have applied rmuTPO in the setting of syngeneic transplantation to accelerate reconstitution of platelets. When applied after transplantation, TPO treatment did not result in accelerated recovery of platelets. In contrast, transplantation of BM cells derived from donors that had been pretreated with TPO for S days resulted in significantly accelerated recovery not only of platelets but also of erythro-
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Platelets (x10 /l) 1 .ooo - For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From Days After Transplantation cytes. Our data suggest that pretreatment of donors with TPO may be an effective way of accelerating platelet reconstitution after myeloablative chemo/radiotherapy and autologous stem cell transplantation. The finding that TPO treatment after transplantation did not enhance reconstitution of platelets is unexpected. Previously, we and others have shown that application of IL-6 after myelosuppressive chemotherapy or sublethal irradiation results in enhanced recovery of platelets." Because TPO administration to healthy donor animals is much more effective than any other single cytokine in inducing thrombocytosis, administration of TPO would likely accelerate recovery of platelets. A lack of activity in this setting may be related to the dose and schedule applied (20 kU/d for S to 10 days), ie, the dose being too low or the duration of treatment being too short. However, the dose was sufficient to induce thrombocytosis after 5 days of treatment in healthy steady-state donor animals. A prolonged administration of TPO for 14 days (days 1 through 14) using a dose of 30 kU/ d sc was similarly ineffective in enhancing platelet recovery after transplantation. However, it should be considered that endogenous TPO levels after lethal irradiation may be increased to a similar degree as observed after exogenous administration. In a model for prolonged thrombocytopenia, involving the use of carboplatin and sublethal irradiation, a similar dose did accelerate platelet reconstitution.'' Nevertheless, the possibility is not excluded that higher doses of TPO when administered for a longer period of time would have an effect on platelet recovery.
An alternative application of TPO in the marrow transplant setting is its use in donors, before BM procurement. Donor mice treated for 5 days with TPO had a 2.5-fold increase in circulating platelets. BM biopsy samples of these donors showed increased numbers of megakaryocytes (data not shown) and semisolid cultures showed significant increases in hematopoietic progenitor cell numbers. Transplantation of lo5 BM cells derived from TPO-treated donors are expressed as means of 20 mice in two experiments. * P < .05; **P < ,005.
resulted in accelerated platelet reconstitution after transplantation. In addition, platelet nadirs were also significantly improved. There appeared to be no additional advantage of posttransplantation treatment with TPO in recipients transplanted with in vivo modified BM cells. The accelerated recovery under these conditions may be due to transplanting increased numbers of megakaryocytic progenitor cells or may be related to transplanting more mature megakaryocytic progenitor cells. To study the influence of cell dose on the rate of recovery, animals were transplmted with increasing numbers of BM cells derived from TPO-treated donors. In comparison with transplantation of equal numbers of BM cells derived from saline-treated control donors, reconstitution of platelets was faster at all cell doses studied. Therefore, both the maturation status of the transplanted megakaryocytic cells and cell numbers may be important factors responsible for this effect. In addition, our data may imply that relatively mature progenitor cells are responsible for early reconstitution after transplantation. Although we did not specifically study the long-term repopulating ability of the TPOmodified marrow cells, mice have been observed until 3 months after transplantation without any evidence of late graft failure.
In addition to an enhanced recovery of platelets, transplantation of in vivo modified BM cells also accelerated the reconstitution of erythrocytes and resulted in higher erythrocyte nadir counts. The possibility was considered that this effect was indirectly related to platelet counts and reflected to bleeding tendency in association with platelet numbers. Therefore, in an additional experiment tail-vein bleedings were omitted until the time of platelet nadir, day 12. At this stage, recipient animals were killed and the numbers of erythroid progenitor cells were assessed in the BM. In these recipients, erythrocyte counts were also significantly increased in comparison with controls transplanted with unmodified BM cells. Because the number of BFU-Es in the marrow and reticulocyte counts in the blood were increased For personal use only. on September 14, 2017. by guest www.bloodjournal.org From in recipients of TPO-modified BM cells, this effect most likely reflects a direct stimulatory activity of TPO on erythropoiesis. There are two explanations for this observation, one being the expression of c-Mpl on erythroid progenitor cells and the other being cross-reactivity of Mpl-ligand with the homologous EPO receptor. Recent data indicate that some erythroid progenitor cells may express c-MplzO and can be directly stimulated in vitro by TPO." Thus, the stimulatory effect on erythropoiesis may be directly related to the expression of c-Mpl on erythroid progenitor cells.
In summary, our data suggest that transplantation of BM cells derived from TPO-pretreated donors may be an effective and alternative method to accelerate the reconstitution of platelets and erythrocytes using a single cytokine in the setting of autologous stem cell transplantation.
